BNP Paribas Financial Markets Sells 21,416 Shares of United Therapeutics Co. (NASDAQ:UTHR)

BNP Paribas Financial Markets cut its stake in United Therapeutics Co. (NASDAQ:UTHR) by 38.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 34,192 shares of the biotechnology company’s stock after selling 21,416 shares during the period. BNP Paribas Financial Markets’ holdings in United Therapeutics were worth $12,253,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. acquired a new stake in shares of United Therapeutics during the first quarter worth $219,000. Cetera Advisors LLC acquired a new stake in United Therapeutics during the 1st quarter worth about $475,000. GAMMA Investing LLC raised its position in shares of United Therapeutics by 84.8% in the 2nd quarter. GAMMA Investing LLC now owns 390 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 179 shares in the last quarter. DNB Asset Management AS lifted its stake in shares of United Therapeutics by 18.3% in the 2nd quarter. DNB Asset Management AS now owns 7,800 shares of the biotechnology company’s stock valued at $2,485,000 after purchasing an additional 1,208 shares during the period. Finally, Park Avenue Securities LLC boosted its position in shares of United Therapeutics by 30.4% during the 2nd quarter. Park Avenue Securities LLC now owns 2,037 shares of the biotechnology company’s stock valued at $649,000 after purchasing an additional 475 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, Director Nilda Mesa sold 224 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total value of $92,350.72. Following the transaction, the director now owns 5,783 shares in the company, valued at $2,384,215.24. The trade was a 3.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 127,227 shares of company stock valued at $47,398,820. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Down 2.0 %

UTHR stock opened at $370.49 on Monday. The stock’s 50 day moving average is $367.77 and its 200-day moving average is $335.65. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The firm has a market capitalization of $16.54 billion, a PE ratio of 16.27, a P/E/G ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.38 EPS. On average, equities research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on UTHR shares. LADENBURG THALM/SH SH boosted their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, August 20th. Argus raised their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.